Adoption of ICHRAs Points to Broader Challenges in Commercial Health Insurance

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗶𝗴𝗻𝗮𝗹

Individual coverage health reimbursement arrangements, or ICHRAs, have seen a steady rise in employer adoption over the past several renewal cycles. Rather than sponsoring a group health plan, employers provide a fixed stipend and direct employees to purchase individual coverage on their state's ACA exchange.

The appeal is straightforward. Individual ACA premiums are priced using age-banded benchmark rates, not group experience rating. For an employer whose group has a poor claims history, that difference can look like meaningful relief.

ICHRA enrollment still represents less than 10% of the employer health plan market, and it is not expected to become a dominant funding model in the near term. But the conversation around it is growing faster than the enrollment numbers suggest. A recent employee benefits industry report found that more than half of advisors are now regularly incorporating ICHRAs into discussions with their employer clients.

𝗛𝗣𝗫 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲

ICHRA adoption is often framed as employers modernizing their benefits strategy.

That is the wrong read.

In practice, the employers moving fastest toward ICHRAs are not doing so out of enthusiasm for the individual market. They are doing so because their group plan's experience rating has become unmanageable, and the ACA benchmark rate offers a way out.

That distinction matters, because a poor experience rating is not a verdict on the group market. It is a signal about how healthcare is being purchased within it.

Conventional carrier-bundled plans price every claim through a single sourcing channel. A specialty medication, a facility charge, a procedure: whatever the carrier's network and PBM have negotiated is the price, full stop. There is no mechanism to evaluate whether that price reflects fair market value or simply the path of least resistance.

That single price then becomes the basis for next year's underwriting.

Employers who unbundle their plan, evaluating provider contracting, pharmacy purchasing, administration, and risk financing independently, routinely find that the same care can be sourced more efficiently without changing the treatment plan. A specialty drug billed at $150,000 annually is not uncommonly available for a fraction of that cost through a different purchasing channel, with the same physician, the same medication, and the same outcome.

That is the opportunity ICHRAs skip past entirely.

𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀

Moving employees to the individual market comes with real costs beyond the premium line.

Plan administration, member advocacy, and claims support largely disappear. There is no one coordinating on the employee's behalf when a claim is denied or a provider is out of network. And the employer's role in the benefit, the thing that ties healthcare support to the culture and retention story of the organization, becomes one step removed.

None of that shows up in a premium comparison, but it shows up in the employee experience.

𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗔𝗵𝗲𝗮𝗱

ICHRA enrollment is unlikely to become a defining feature of the employer health plan market anytime soon. But the fact that a majority of advisors are now raising it in client conversations says something important on its own. It reflects just how much pressure employers are feeling from conventional group renewals, and how readily an exit is being offered as the answer.

But for employers willing to ask that question first, the calculus often changes. A poor renewal is rarely a population health problem. More often, it is a purchasing problem, one that an unbundled plan structure is built to solve without asking employees to give up the group benefit at all.

The employers best positioned over the next several years will not be the ones who exit the group market fastest. They will be the ones who figure out how to purchase healthcare more intelligently within it.